• CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY - C3I

C3i

ACCELERATING MARKET ACCESS OF BREAKTHROUGH
INNOVATIONS TO FIGHT CANCER

News

C3i’s Biomarker and Diagnostic unit now offers TCR-beta sequencing services

The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce the availability of T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit.
MORE